Renalytix inks partnership with US healthcare provider St Joseph's

Renalytix announced a partnership with St Joseph's Health on Tuesday, to implement an advanced clinical care model designed to improve kidney health in patients with type-2 diabetes and early-stage chronic kidney disease.

The AIM-traded firm said its ‘KidneyIntelX’ platform would be integrated with St Joseph's Health’s care management, to help prevent patients with diabetes and early-stage kidney disease from unnecessarily progressing to significant disease or kidney failure.

It said KidneyIntelX was designed to enable primary care and specialist physicians to understand risk, and would help St Joseph's Health implement medication management, nutrition and education intervention protocols on a timely basis.

St Joseph's Health is part of Trinity Health, one of the largest multi-institutional Catholic health care delivery systems in the United States, serving more than 30 million people across 25 states.

The company said the KidneyIntelX test risk assessment would be available through St Joseph's Hospital's electronic health record (EHR) system, providing access to primary care physicians, endocrinologists, nephrologists, and care teams.

“St Joseph's Health shares our forward-thinking, patient-centric approach to changing the standard of care in kidney health,” said Christine Loftsgaarden, vice-president of commercial partnerships at Renalytix.

“St Joseph's Health's early-stage chronic kidney disease care model, powered by KidneyIntelX, is expected to drive improved clinical and cost outcomes to make healthier kidneys both attainable and sustainable.”

At 1009 GMT, shares in Renalytix were down 0.71% at 844p.